3C | chromosome conformation capture |
4C | circularized chromosome conformation capture |
AR | Androgen Receptor |
CNAs | Copy Number Alterations |
CPC-GENE | Canadian CaP Genome Network |
CR-NEPC | castration resistant neuroendocrine prostate cancer |
CRPC | castration resistant prostate adenocarcinoma |
DDR | Damage Repair |
DSB | double-strand break |
EGFR | epidermal growth factor receptor |
FA | Fanconi anemia |
FISH | fluorescent in-situ hybridization |
HBOC | hereditary breast and ovarian cancer |
HBOC | ovarian cancer |
HPC | hereditary Prostate Cancer |
HR | homologous recombination |
HR | homologous recombination |
ICGC | International Cancer Genome Consortium |
LS MAPK |
Lynch Syndrome Mitogen-activated protein kinase |
MATCH | Molecular Analysis for Therapy Choice |
mCRPC | metastatic castrate resistant prostate cancer |
MMR | Mismatch Repair |
MSI | microsatellite instability |
NCI | National Cancer Institute |
NGS NIH |
Next-Gen sequencing National Institutes of Health |
NHEJ | Non-homologous end joining |
NSCLC | non-small-cell lung cancer |
OMB PARP PI3K |
Office of Management and Budget Poly (ADP-ribose) polymerase Phosphatidylinositol 3- kinase |
PCF | Prostate Cancer Foundation |
SEER SNPs |
Surveillance, Epidemiology, and End Results single-nucleotide polymorphisms |
SSA | single-strand annealing |
SU2C | Stand Up to Cancer |
TCGA | The Cancer Genome Atlas |
TSG | tumor suppressor genes |
WES | Whole exome sequencing |